Boston Scientific Stock Forecast for 2023 - 2025 - 2030
Updated on 06/09/2023
Boston Scientific Stock Forecast and Price Target
If Boston Scientific's stock price reached the average yearlong target of $50.00 given by twenty well-known analysts in recent months, there would be a potential downside of approximately -2.1% from its last closing price in June, 2023. This potential increase is based on a high estimate of $56.00 and a low estimate of $45.00. If you want to buy BSX stock, it might be a good idea to look at its competitors too.
-2.10% Downside
Boston Scientific Fair Value Forecast for 2023 - 2025 - 2030
Boston Scientific's Price has seen impressive growth In the last two years, rising from $41.46 to $42.77 – a growth of 3.16%. In the next year, analysts believe that Fair Value will reach $53.00 – an increase of 23.93%. For the next eight years, the forecast is for Fair Value to grow by 72.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ROG Stock Forecast | Roche Holding | Outperform |
5
|
CHF293.60 | Buy/Sell | CHF384.23 | 24.32% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$100.79 | Buy/Sell | $121.64 | 24.02% |
| DHR Stock Forecast | Danaher Corp | Outperform |
10
|
$235.41 | Buy/Sell | $304.24 | 29.35% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$83.10 | Buy/Sell | $90.05 | 3.49% |
| GE Stock Forecast | General Electric | Outperform |
7
|
$106.07 | Buy/Sell | $107.03 | -17.98% |
Boston Scientific Revenue Forecast for 2023 - 2025 - 2030
Boston Scientific's Revenue has seen impressive growth In the last two years, rising from $10.74B to $11.89B – a growth of 10.74%. In the next year, analysts believe that Revenue will reach $13.79B – an increase of 16.02%. For the next eight years, the forecast is for Revenue to grow by 85.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$249.50 | Buy/Sell | $284.07 | 10.22% |
| SHL Stock Forecast | Siemens Healthineers | Outperform |
18
|
52.52€ | Buy/Sell | 61.61€ | 10.43% |
| MMM Stock Forecast | 3M Co | Hold |
16
|
$100.75 | Buy/Sell | $147.79 | 18.61% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EW Stock Forecast | Edwards Lifesciences | Outperform |
15
|
$83.96 | Buy/Sell | $92.45 | 10.77% |
| 6501 Stock Forecast | Hitachi | Buy |
18
|
¥6.56k | Buy/Sell | ¥0.00 | 29.65% |
| ECL Stock Forecast | Ecolab Inc | Outperform |
18
|
$177.00 | Buy/Sell | $164.25 | -6.78% |
Boston Scientific Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Boston Scientific has seen a decline in its Free Cash Flow, from $1.38B to $1.32B – a 4.29% decrease. Analysts predict that Boston Scientific's Free Cash Flow will increase in the upcoming year, reaching $2.45B. This would represent an increase of 86.06%. Over the next eight years, experts predict that Boston Scientific's Free Cash Flow will grow at a rate of 274.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| RMD Stock Forecast | ResMed | Outperform |
17
|
$214.91 | Buy/Sell | $251.67 | 17.49% |
| GMAB Stock Forecast | Genmab A/S | Outperform |
16
|
kr3.00k | Buy/Sell | kr2.84k | -8.24% |
| CERN Stock Forecast | Cerner | - |
13
|
$94.92 | Buy/Sell | $93.31 | 13.03% |
Boston Scientific Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Boston Scientific's Net Income has decreased from $4.70B to $1.04B – a 77.85% drop! In the next year, analysts predict that Net Income will jump to $2.93B – up 181.07% from the current level. Looking ahead to eight years, experts forecast that Net Income will grow by 301.17%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$41.34 | Buy/Sell | $60.73 | 40.30% |
| 7733 Stock Forecast | Olympus | Outperform |
18
|
¥2.39k | Buy/Sell | ¥0.00 | 32.72% |
| ARGX Stock Forecast | argenx | Buy |
4
|
358.10€ | Buy/Sell | 0.00€ | -0.31% |
Boston Scientific EBITDA Forecast for 2023 - 2025 - 2030
Boston Scientific's EBITDA has seen growth In the last two years, going from $2.84B to $3.10B – a gain of 9.15% In the next year, analysts believe that EBITDA will reach $4.12B – an increase of 32.66%. For the next seven years, the forecast is forEBITDA to grow by 55.85%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CAH Stock Forecast | Cardinal Health | Hold |
13
|
$85.32 | Buy/Sell | $85.19 | -4.48% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$220.74 | Buy/Sell | $278.38 | 24.58% |
| DGX Stock Forecast | Quest Diagnostics | Hold |
10
|
$135.68 | Buy/Sell | $147.77 | 6.50% |
Boston Scientific EBIT Forecast for 2023 - 2025 - 2030
In the last two years, EBIT for Boston Scientific has grown by 9.72%, going from $1.83B to $2.01B. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $3.72B – an increase of 85.37%. Over the next eight years, experts anticipate that EBIT growth for Boston Scientific will be 219.21%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABMD Stock Forecast | Abiomed | - |
16
|
$7.57k | Buy/Sell | $380.00 | -94.49% |
| HOLX Stock Forecast | Hologic Inc | Outperform |
8
|
$84.06 | Buy/Sell | $79.86 | -1.86% |
| FME Stock Forecast | Fresenius Medical Care AG & Co... | Hold |
18
|
42.87€ | Buy/Sell | 32.79€ | -25.36% |
Boston Scientific EPS Price Prediction Forecast for 2023 - 2025 - 2030
Boston Scientific's EPS has seen impressive growth In the last two years, rising from $1.58 to $1.63 – a growth of 3.16%. In the next year, analysts believe that EPS will reach $2.02 – an increase of 23.93%. For the next eight years, the forecast is for EPS to grow by 72.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£11.60 | Buy/Sell | £15.98 | 39.22% |
| SIEMENS Stock Forecast | Siemens | Hold |
16
|
Rp2.89k | Buy/Sell | Rp2.12k | -10.17% |
| PEN Stock Forecast | Penumbra | Buy |
9
|
$314.68 | Buy/Sell | $0.00 | -7.84% |
Site Navigation
.jpg)